SCHOLAR ROCK HOLDING CORPORATION APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $19.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $19.66M, a 19.53% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $18.25M, a 36.02% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $18.33M, a 89.96% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $24.43M, a 162.38% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $75.60M, a 106.40% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $36.63M, a 34.95% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $27.14M, a 2.02% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $27.70M, a 19.66% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.66M 10-Q · filed 2026-08-06 | $37.91M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $18.25M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $75.60M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $18.33M 10-Q · filed 2025-11-14 | $42.76M derived: sum of 2 quarters · filed 2026-08-06 | $56.18M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $24.43M 10-Q · filed 2026-08-06 | $37.85M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $13.41M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $36.63M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $9.65M 10-Q · filed 2025-11-14 | $18.96M derived: sum of 2 quarters · filed 2025-11-14 | $27.13M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $9.31M 10-Q · filed 2025-11-14 | $17.48M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $8.16M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $27.14M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $7.20M 10-Q · filed 2024-11-12 | $14.02M derived: sum of 2 quarters · filed 2024-11-12 | $20.19M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $6.82M 10-Q · filed 2024-11-12 | $12.99M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $6.17M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $27.70M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $7.92M 10-Q · filed 2023-11-07 | $14.71M derived: sum of 2 quarters · filed 2023-11-07 | $21.54M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $6.79M 10-Q · filed 2023-11-07 | $13.62M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $6.83M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $23.15M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | $6.15M 10-Q · filed 2022-11-14 | $12.38M derived: sum of 2 quarters · filed 2022-11-14 | $17.05M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $6.23M 10-Q · filed 2022-11-14 | $10.90M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $4.67M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $11.18M 10-K · filed 2022-03-07 | |||
| 2020-09-30 | $4.04M 10-Q · filed 2021-11-09 | $6.43M derived: sum of 2 quarters · filed 2021-11-09 | $8.64M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $2.40M 10-Q · filed 2021-11-09 | $4.61M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $2.21M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $7.97M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | $2.69M 10-Q · filed 2020-11-09 | $4.50M derived: sum of 2 quarters · filed 2020-11-09 | $6.12M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $1.81M 10-Q · filed 2020-11-09 | $3.43M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $1.62M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $5.21M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $1.49M 10-Q · filed 2019-11-12 | $2.58M derived: sum of 2 quarters · filed 2019-11-12 | $3.06M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $1.09M 10-Q · filed 2019-11-12 | $1.57M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $482.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $1.48M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |